BPC-157 and TB-500 Together: Wolverine Stack Questions, Answered

Both peptides belong to what a 2026 review calls a "gray market" of unapproved peptides with scarce human safety data ⁴. Each component has its own record: BPC-157 and TB-500. The blend itself is covered on the BPC-157 + TB-500 blend reference page.

The only experiment that tested the pair against each peptide alone was a rat tendon study ¹.

The clinic quoted by FDA used the name for its healing claims about BPC-157 ¹³. The same nickname is now attached to the two-peptide blend, also sold as the "Wolverine blend" or "BPC-157/TB-500 blend".

BPC-157 was linked to blood vessel growth signalling in cells and rats ¹¹. Full-length thymosin beta-4 and a non-acetylated version of TB-500's sequence were linked to skin wound repair in mice ¹². Marketed TB-500 is acetylated, so that mouse finding does not transfer directly ¹⁴.

The rat tendon study authors suggested the two may act on shared downstream pathways, which could explain the lack of an added effect. They called this a hypothesis needing confirmation ¹.

In the 2026 rat study, 32 animals with repaired Achilles tendons were randomised to control, BPC-157, TB-500 or both ¹. The authors described the study as exploratory ¹. Results compared with untreated controls:

No published study has given people the BPC-157 + TB-500 pair. In one uncontrolled knee-pain chart review, 4 patients received BPC-157 with thymosin beta-4 (the full protein, not TB-500) ². Three were recorded as improved, with no control group or validated measures ².

A 2026 case report described three nerve-injury patients treated with several drugs including peptides ¹⁰. It does not say which peptides each patient received, and its authors state causality cannot be established ¹⁰.

FDA describes both peptides as raising possible immune and impurity concerns ⁹. See the BPC-157 + TB-500 combination page for the evidence summary.

Other rat studies of BPC-157 alone report faster tendon healing ¹³. A 2026 systematic review found only three small human BPC-157 studies, all of very low certainty ¹⁶.

FDA found no human data for TB-500 itself ¹⁴. A single rat study cannot settle which peptide is "better" for people. The full side-by-side is in BPC-157 vs TB-500.

A 2026 review says claimed musculoskeletal effects of these peptides remain unsubstantiated by human trials ³. The knee-pain review used telephone recall and no validated outcome measures ².

A 2026 scoping review of six marketed peptides found about two-thirds of publications were animal studies ³. Human studies were few and mostly uncontrolled ³. WADA bans both peptides, which reflects doping concern, not proof of effect ⁷.

The rat results are in the table above ¹. The four knee-pain patients received the full protein, not TB-500, and rated their own pain by phone months later ². Without a control group, such reports cannot separate a peptide effect from placebo or natural recovery ¹⁶.

A 2026 review lists contamination, impurities and inaccurate labelled content among the risks of unregulated injectable peptides, including these two ⁵. It also lists theoretical abnormal blood vessel growth ⁵. Another review classes both as investigational with uncertain safety profiles ⁶.

FDA found no human exposure data for TB-500 and limited safety information for BPC-157 ^9,14. The skin and gum reaction is described in FDA's BPC-157 briefing ¹³. Mixing two poorly characterised products adds uncertainty rather than removing it.

FDA found no dose-response data for either peptide ^13,14. A 2026 review noted that amounts and routes vary widely across the literature ³. For what human studies did and did not report, see BPC-157 + TB-500 dosage in human studies.

A single purity figure for a two-peptide vial does not say which peptide it describes. A useful certificate shows each peptide by mass spectrometry, each resolved in the chromatogram, and a net content for each. See how to read a certificate of analysis and what are peptide blends?

An oral BPC-157 phase 1 trial was registered years ago, but FDA reports no outcome data from it ¹³. Our guide on why most peptides are injected explains why oral peptides are hard to absorb.

FDA found no human pharmacokinetic data for BPC-157 after oral, injected, nasal or skin use ¹³. It found no human exposure data for TB-500 at all ¹⁴. Published detection methods cited here cover TB-500 in horses ¹⁵.

FDA lists both among substances whose compounding nominations were withdrawn and that may present significant safety risks ⁹. FDA's Pharmacy Compounding Advisory Committee discussed both on July 23, 2026, and voted on whether each should be placed on the 503A list ¹⁸. FDA has not published minutes or announced a decision, and the 503A list is unchanged ¹⁸.

FDA staff briefings had proposed not adding either peptide ^13,14. A staff briefing is input to the committee, not FDA's final word. Our guide to peptide legality in the United States explains what research-use-only labelling means.

S0 also covers unlisted unapproved substances, so absence from the list would not mean permission ⁷. See peptides and sport ¹⁵.

That rat study found no added effect from combining BPC-157 and TB-500 ¹. Adding more components does not add evidence. See GLOW, KLOW and our guide to peptide blends.

KPV reduced intestinal inflammation in cell lines and mouse colitis models ¹⁷. FDA states it has not identified any human exposure data for KPV ⁹. For BPC-157 against KPV, see BPC-157 vs KPV, and for the blend that includes KPV, see KLOW.

The rat study was designed as a research model, not to guide pet care ¹. For the evidence on the mixture, see the BPC-157 + TB-500 blend reference page.